Journal article

A Practical Approach to the Use of Conventional Synthetic, Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for the Treatment of Inflammatory Arthritis in Patients with a History of Malignancy

Peter KK Wong, Hanish Bagga, Claire Barrett, Geoff Chong, Patrick Hanrahan, Teja Kodali, Mona Marabani, H Miles Prince, John Riordan, Phillip Swarbrick, Ray White, Laurel Young

CURRENT RHEUMATOLOGY REPORTS | SPRINGER | Published : 2018

Abstract

PURPOSE OF REVIEW: Conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) have been used in the treatment of inflammatory arthritis (IA) for many years. More recently, biologic (bDMARDs) and targeted synthetic (tsDMARDs) DMARDs have further improved treatment. Due to increased patient longevity and effective oncology treatment, rheumatologists often encounter patients with IA and previous malignancy. The immunosuppressive effect of DMARDs causes concern regarding impaired tumour surveillance with a potential increased risk of malignancy. We reviewed the literature regarding the risk of malignancy in patients on cs-/b-/tsDMARDS and sought to provide practical advice regardin..

View full abstract